Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for Seagen (SGEN)

Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.

Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug

Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.

Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug

Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.

Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut

Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.

Seattle Genetics (SGEN) Q3 Earnings and Revenues Top Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 4475.00% and 166.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev

Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.

Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes

Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.

Seattle Genetics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Seattle Genetics.

Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival

Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Seattle Genetics Up on Two New Oncology Deals With Merck

Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.

Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug

Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America

Stock Market News for Sep 15, 2020

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

M&A Activities Intensify in Pharma Industry

M&A Activities Intensify in Pharma Industry.

Mark Vickery headshot

No Econ Data, but Big Biopharma News

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Seattle Genetics (SGEN) Down 10.2% Since Last Earnings Report: Can It Rebound?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.